Comparison
Sermorelin vs Testosterone
Side-by-side of Sermorelin and Testosterone. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Sermorelin
Sermorelin peptide therapy uses a 29-amino-acid GHRH analog to raise endogenous GH. Dosing, half-life, sermorelin vs ipamorelin, and safety.
Testosterone
Testosterone replacement therapy for hypogonadism: TRAVERSE 2023 cardiovascular data, cypionate dosing, body composition gains, Schedule III status.
Effects at a glance
Sermorelin
- •Synthetic 29-amino-acid GHRH fragment; FDA approved 1997 for pediatric GH deficiency as Geref
- •Voluntarily discontinued by Serono in 2008 for commercial reasons; not safety-related
- •Compounded by 503A/503B pharmacies for off-label adult anti-aging and body-composition use
- •Produces physiologic pulsatile GH release; ~10 to 20 minute plasma half-life
- •Standard anti-aging clinic protocol: 200 to 500 mcg subcutaneously pre-bed, often with ipamorelin
- •Banned by WADA under S2 (peptide hormones, growth factors)
Testosterone
- •Primary androgen; FDA approved for hypogonadism with confirmed deficiency and symptoms
- •Testosterone Trials (2016) showed sexual function and bone density improvements in older hypogonadal men
- •TRAVERSE 2023 (n=5,246) found non-inferiority on MACE versus placebo, with higher AF and PE rates
- •Schedule III controlled substance in US; WADA banned in sport
- •Aromatizes to estradiol; converts to DHT via 5-alpha reductase; both metabolites matter clinically
- •Erythrocytosis (HCT above 54%) affects 5 to 25% of users and is the most common dose-limiting effect
Side-by-side
| Attribute | Sermorelin | Testosterone |
|---|---|---|
| Category | peptide | hormone |
| Also known as | Sermorelin acetate, GRF 1-29, Geref, GHRH (1-29) NH2 | TRT, testosterone replacement therapy, testosterone cypionate, testosterone enanthate, Androgel, Testim |
| Half-life (hr) ↗ | 0.25 | 192 |
| Typical dose (mg) ↗ | 0.3 | 150 |
| Dosing frequency | 1-2x daily | weekly to twice-weekly (cypionate/enanthate IM or SC); daily (topical, oral); every 3 to 6 months (pellet) |
| Routes | subcutaneous | intramuscular, subcutaneous, topical, buccal, subcutaneous (pellet), oral |
| Onset (hr) | 0.25 | 24 |
| Peak (hr) | 0.5 | 72 |
| Molecular weight | 3357.88 | 288.42 |
| Molecular formula | C149H246N44O42S | C19H28O2 |
| Mechanism | Synthetic 29-amino-acid GHRH fragment that binds the GHRH receptor on pituitary somatotrophs to stimulate endogenous pulsatile GH synthesis and release while preserving the GH-IGF-1 negative feedback loop. | Androgen receptor agonist driving anabolic gene transcription in muscle, bone, brain, and androgen-sensitive tissue. Aromatized to estradiol and 5-alpha-reduced to DHT, both with distinct downstream effects. |
| Legal status | FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA | Schedule III controlled substance (US); WADA banned |
| WADA status | banned | banned |
| DEA / Rx | Rx only via compounding (no controlled-substance schedule) | Schedule III |
| Pregnancy | Category C (historical labeling); not recommended in pregnancy | Category X; contraindicated in pregnancy (virilizing effect on female fetus) |
| CAS | 86168-78-7 | 58-22-0 |
| PubChem CID | 16129617 | 6013 |
| Wikidata | Q416620 | Q150726 |
Safety profile
Sermorelin
Common side effects
- injection-site pain or irritation
- transient flushing
- headache
- vivid dreams (pre-bed dosing)
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- diabetic retinopathy (theoretical)
- untreated hypothyroidism
Interactions
- ipamorelin: synergistic GH release via parallel GHRH and ghrelin pathways; standard anti-aging clinic pairing(minor)
- CJC-1295: pharmacologically redundant (both GHRH-pathway); typically not stacked(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response; reduce expected efficacy(moderate)
- levothyroxine (untreated hypothyroidism): untreated hypothyroidism blunts GH response; correct thyroid first(moderate)
Testosterone
Common side effects
- erythrocytosis
- acne
- oily skin
- fluid retention
- increased body hair
- fertility suppression
- injection-site reactions
Contraindications
- active prostate cancer
- active breast cancer
- untreated severe sleep apnea
- untreated severe BPH
- uncontrolled heart failure
- polycythemia at baseline
Interactions
- warfarin: may potentiate anticoagulant effect; monitor INR(moderate)
- insulin: may improve insulin sensitivity; monitor glucose in diabetics(moderate)
- 5-alpha reductase inhibitors (finasteride): blocks DHT conversion; reduces some androgen effects(moderate)
- aromatase inhibitors (anastrozole): lowers estradiol; risk of over-suppression(moderate)
Which Should You Take?
Testosterone comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Sermorelin is the right call when one of the conditionals below applies.
- → If your priority is growth-hormone axis, pick Sermorelin.
- → If your priority is healthspan extension, pick Sermorelin.
- → If your priority is hormonal optimization, pick Testosterone.
- → If your priority is sexual function, pick Testosterone.
Edge case: If you cannot self-administer injections, Testosterone is the only oral option in this pair.
Default choice: Testosterone. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Sermorelin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Sermorelin and Testosterone?
Sermorelin and Testosterone differ in category (peptide vs hormone), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Sermorelin or Testosterone?
Sermorelin half-life is 0.25 hours; Testosterone half-life is 192 hours.
Can you stack Sermorelin with Testosterone?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper